AIM
EIGR

Alambic Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Alambic Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-68
Closed -$45K – 532
2015
Q4 		$45K Buy
+68
New +$38.5K 0.03% 360

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alambic Investment Management's EIGR Position: Q1 2016 in Review

Alambic Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2016, closing a stake of 68 shares — an estimated $45K sold.

Alambic Investment Management first reported a position in EIGR in Q4 2015 and held it in 1 quarter. The position peaked at $45K in Q4 2015. 30 funds tracked by Wall St. Rank hold EIGR as of Q1 2016.

  • Alambic Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Alambic Investment Management sold 68 Eiger BioPharmaceuticals, Inc. shares in Q1 2016, an estimated $45K.
  • Alambic Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Alambic Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $45K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2016.

Based on Alambic Investment Management's 13F filing for Q1 2016, filed 5 May 2016.